deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT05653427

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Sponsor: Janssen Research & Development, LLC

Conditions Carcinoma, Hepatocellular
Interventions Amivantamab
Updated 17 times since 2023 Last updated: Jan 9, 2025 Started: Dec 8, 2022 Primary completion: Oct 10, 2023 Completion: Oct 10, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

N\~15 subjects data analysis did not meet statistical consideration of ORR and study primary/secondary objectives were not met. Enrollment was terminated for futility

Other terminated trials from Janssen Research & Development, LLC

More terminations from Janssen Research & Development, LLC

Listed as NCT05653427, this PHASE2 trial focuses on Carcinoma, Hepatocellular and remains terminated or withdrawn. Sponsored by Janssen Research & Development, LLC, it has been updated 17 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Feb 2025 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jan 2025 — Feb 2025 [monthly]

    Terminated PHASE2

  4. Nov 2024 — Jan 2025 [monthly]

    Terminated PHASE2

  5. Sep 2024 — Nov 2024 [monthly]

    Terminated PHASE2

▶ Show 12 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  2. Jan 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  3. Dec 2023 — Jan 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  5. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  6. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  7. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  8. Jun 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  9. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  10. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  11. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jan 2023 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Research & Development, LLC
Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Chang Chun Shi, China , Changsha, China , Chengdu, China , Chongqing, China , Dalian, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Nanchang, China and 2 more locations